Effects of genetic susceptibility for type 2 diabetes on the evolution of glucose homeostasis traits before and after diabetes diagnosis: Data from the D.E.S.I.R. study

Diabetes

Volumn 60, Issue 10, 2011, Pages 2654-2663

  Gautier, Alain ^a   Roussel, Ronan ^b   Lange, Céline ^c,d   Piguel, Xavier ^a   Cauchi, Stéphane ^e   Vol, Sylviane ^f   Froguel, Philippe ^e,g   Balkau, Beverley ^c,d   Bonnet, Fabrice ^a  

^a SERVICE DE RHUMATOLOGIE   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e CNRS   (France)

^f Institut Inter Regional Pour la Sante   (France)

^g HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; GLYCOSYLATED HEMOGLOBIN; TRANSCRIPTION FACTOR 7 LIKE 2;

ADULT; AGED; ALLELE; ARTICLE; CELL SECRETION; FAMILY HISTORY; FEMALE; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE; HOMEOSTASIS; HUMANS; MALE; MIDDLE AGED; TIME FACTORS;

EID: 80053402818     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db10-1442     Document Type: Article

References (29)

1. Festa A, Williams K, D'Agostino R Jr, Wagenknecht LE, Haffner SM. The natural course of beta-cell function in nondiabetic and diabetic individuals: the Insulin Resistance Atherosclerosis Study. Diabetes 2006;55:1114-1120 (Pubitemid 44100189)
2. Festa A, Williams K, Hanley AJ, Haffner SM. Beta-cell dysfunction in subjects with impaired glucose tolerance and early type 2 diabetes: comparison of surrogate markers with first-phase insulin secretion from an intravenous glucose tolerance test. Diabetes 2008;57:1638-1644
3. Lorenzo C, Wagenknecht LE, D'Agostino RB Jr, Rewers MJ, Karter AJ, Haffner SM. Insulin resistance, beta-cell dysfunction, and conversion to type 2 diabetes in a multiethnic population: the Insulin Resistance Atherosclerosis Study. Diabetes Care 2010;33:67-72
4. Ferrannini E, Nannipieri M, Williams K, Gonzales C, Haffner SM, Stern MP. Mode of onset of type 2 diabetes from normal or impaired glucose tolerance. Diabetes 2004;53:160-165 (Pubitemid 38044710)
5. Guerrero-Romero F, Rodríguez-Morán M. Assessing progression to impaired glucose tolerance and type 2 diabetes mellitus. Eur J Clin Invest 2006;36:796-802 (Pubitemid 44569968)
6. Xiang AH, Wang C, Peters RK, Trigo E, Kjos SL, Buchanan TA. Coordinate changes in plasma glucose and pancreatic beta-cell function in Latino women at high risk for type 2 diabetes. Diabetes 2006;55:1074-1079 (Pubitemid 44100184)
7. Lyssenko V, Almgren P, Anevski D, et al.; Botnia study group. Predictors of and longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetes. Diabetes 2005;54:166-174 (Pubitemid 40105109)
8. Weir GC, Bonner-Weir S. Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes 2004;53(Suppl. 3):S16-S21 (Pubitemid 39564517)
9. Tabák AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimäki M, Witte DR. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet 2009;373:2215-2221
10. Lyssenko V, Jonsson A, Almgren P, et al. Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med 2008;359:2220-2232
11. Munoz J, Lok KH, Gower BA, et al. Polymorphism in the transcription factor 7-like 2 (TCF7L2) gene is associated with reduced insulin secretion in nondiabetic women. Diabetes 2006;55:3630-3634 (Pubitemid 44923627)
12. Loos RJ, Franks PW, Francis RW, et al. TCF7L2 polymorphisms modulate proinsulin levels and beta-cell function in a British Europid population. Diabetes 2007;56:1943-1947 (Pubitemid 47025464)
13. Gloyn AL, Braun M, Rorsman P. Type 2 diabetes susceptibility gene TCF7L2 and its role in beta-cell function. Diabetes 2009;58:800-802
14. Helgason A, Pálsson S, Thorleifsson G, et al. Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution. Nat Genet 2007;39:218-225 (Pubitemid 46184353)
15. Hivert MF, Jablonski KA, Perreault L, et al.; DIAGRAM Consortium; Diabetes Prevention Program Research Group. Updated genetic score based on 34 confirmed type 2 diabetes loci is associated with diabetes incidence and regression to normoglycemia in the Diabetes Prevention Program. Diabetes 2011;60:1340-1348
16. Heni M, Ketterer C, Thamer C, et al. Glycemia determines the effect of type 2 diabetes risk genes on insulin secretion. Diabetes 2010;59:3247-3252
17. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010;33(Suppl. 1):S62-S69
18. Laspa E, Christen A, Efstathiadou Z, Johnston DG, Godsland IF. Long-term changes and variability in diabetes risk factors prior to the development of impaired glucose homeostasis. Diabet Med 2007;24:1269-1278 (Pubitemid 47621792)
19. Sattar N, McConnachie A, Ford I, et al. Serial metabolic measurements and conversion to type 2 diabetes in the West of Scotland Coronary Prevention Study: specific elevations in alanine aminotransferase and triglycerides suggest hepatic fat accumulation as a potential contributing factor. Diabetes 2007;56:984-991 (Pubitemid 46525076)
20. Lyssenko V, Lupi R, Marchetti P, et al. Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest 2007;117:2155-2163 (Pubitemid 47219560)
21. Florez JC, Jablonski KA, Bayley N, et al.; Diabetes Prevention Program Research Group. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med 2006;355:241-250 (Pubitemid 44079339)
22. Cauchi S, Meyre D, Choquet H, et al.; DESIR Study Group. TCF7L2 variation predicts hyperglycemia incidence in a French general population: the Data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR) study. Diabetes 2006;55:3189-3192 (Pubitemid 44923661)
23. Villareal DT, Robertson H, Bell GI, et al. TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action. Diabetes 2010;59:479-485
24. Hadjiyanni I, Baggio LL, Poussier P, Drucker DJ. Exendin-4 modulates diabetes onset in nonobese diabetic mice. Endocrinology 2008;149:1338-1349 (Pubitemid 351397945)
25. Kim SJ, Nian C, Doudet DJ, McIntosh CH. Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell modulation. Diabetes 2009;58:641-651
26. Sherry NA, Chen W, Kushner JA, et al. Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells. Endocrinology 2007;148:5136-5144 (Pubitemid 350012634)
27. Blandino-Rosano M, Perez-Arana G, Mellado-Gil JM, Segundo C, Aguilar-Diosdado M. Anti-proliferative effect of pro-inflammatory cytokines in cultured beta cells is associated with extracellular signal-regulated kinase 1/2 pathway inhibition: protective role of glucagon-like peptide-1. J Mol Endocrinol 2008;41:35-44
28. Tourrel C, Bailbe D, Lacorne M, Meile MJ, Kergoat M, Portha B. Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagonlike peptide-1 or exendin-4. Diabetes 2002;51:1443-1452 (Pubitemid 34826610)
29. Song Y, Manson JE, Tinker L, et al. Insulin sensitivity and insulin secretion determined by homeostasis model assessment and risk of diabetes in a multiethnic cohort of women: the Women's Health Initiative Observational Study. Diabetes Care 2007;30:1747-1752 (Pubitemid 47036347)